Browse the evidence

The primary efficacy endpoint is percentage change in body weight.

The trial will measure how effective efsubaglutide alfa is at reducing body weight.

Tirzepatide significantly improved physical function compared with placebo, with a mean difference of 10.10 points in the IWQOL-Lite-CT physical function subscale.

Practitioners can consider tirzepatide as an effective treatment to enhance physical function in adults with overweight or obesity.

The guidelines provide context-specific recommendations tailored to individual patient needs.

Healthcare providers should customize obesity management strategies for individual patients.

The guidelines include recommendations for situations with limited resources.

Providers in resource-limited settings can utilize these guidelines to optimize care.

Once-monthly maridebart has produced clinically meaningful weight loss of approximately 12–16% in adults without diabetes and 8–12% in those with type 2 diabetes.

Practitioners can expect significant weight loss outcomes with once-monthly maridebart in their patients.

Among a subgroup of members on tirzepatide, semaglutide, or with exposure to both, 86.5% of members had at least a 5% reduction in body weight from baseline at 6 months.

These medications are effective for significant weight loss in adherent patients.

Cardiac rehabilitation (CR) significantly improves functional capacity, cardiovascular risk factors, and quality of life in patients with obesity.

Practitioners should implement CR programs to enhance health outcomes in obese patients with cardiovascular issues.

Tailored cardiac rehabilitation programs integrating individualized exercise, nutritional support, and pharmacotherapy show short-term benefits.

Implementing tailored CR programs can enhance short-term outcomes for obese patients.

Incretin polyagonists significantly reduced body weight compared to placebo (MD -11.47; 95% CI: -14.00 to -8.95).

Incretin polyagonists can be considered effective for weight management in obese patients.

Significant reductions were observed in waist circumference (MD -9.40; 95% CI: -11.91 to -6.89).

Incretin polyagonists may help reduce waist circumference in obese individuals.

Precision nutrition may mitigate adverse effects and weight recovery during pharmacotherapy.

Incorporating precision nutrition can enhance the effectiveness of obesity treatments.

Integrating nutrition and incretin therapies may improve weight-loss durability and adherence.

Practitioners should consider integrated approaches for better long-term weight management.

GLP-1 receptor agonists (GLP-1 RAs) are used to treat type 2 diabetes and obesity due to benefits in glycemic control, weight loss, and cardiovascular risk reduction.

Practitioners should consider GLP-1 RAs for managing type 2 diabetes and obesity.

Both tirzepatide and semaglutide significantly improved weight, body mass index, hemoglobin A1c, fasting plasma glucose, and triglyceride levels in solid-organ transplant recipients.

Both medications can be considered effective options for managing diabetes in transplant patients.

Participants without type 2 diabetes (T2D) achieved significantly greater weight loss than those with T2D, with a median weight loss of 11.21% vs 5.48%, P < 0.001.

Practitioners should consider diabetes status when setting weight loss expectations for patients.

Tirzepatide was associated with greater weight loss compared with semaglutide, with a median weight loss of 8.60% vs 5.62%, P = 0.023.

Clinicians may prefer tirzepatide over semaglutide for better weight loss outcomes.

Younger age, tirzepatide use, and GLP1 treatment naivety were identified as determinants of faster achievement of ≥10% weight loss.

Understanding these determinants can help tailor weight loss strategies for individuals.

Adding testosterone undecanoate to tirzepatide in late responders resulted in significantly greater body weight and fat mass reduction compared to tirzepatide monotherapy (P<0.05).

Clinicians may consider adding testosterone therapy to enhance weight loss outcomes in specific patient populations.

Testosterone undecanoate addition led to significant lean body mass recovery compared to tirzepatide monotherapy (66.1±3.1 kg vs. 63.4±3.0 kg, P<0.01).

Adding testosterone therapy may help preserve or enhance muscle mass in patients struggling with weight loss.

Approximately two-thirds of patients showed stable weight or continued weight loss during the 6 months following their last semaglutide or tirzepatide prescription.

Practitioners can expect that a significant portion of patients may maintain or lose weight after discontinuing GLP-1RA.

Tirzepatide treatment was associated with a mean percentage weight change of -13.3% for 5 mg and -21.3% for 15 mg compared to placebo from randomization to 72 weeks among participants using weight-inducing medications in SURMOUNT-1.

Practitioners can consider tirzepatide as an effective option for weight loss in patients requiring weight-inducing medications.

In SURMOUNT-3, the mean percentage weight change for the maximum tolerated dose of tirzepatide was -26.1% from randomization to 72 weeks among participants using weight-inducing medications.

Practitioners can consider higher doses of tirzepatide for significant weight loss in patients on weight-inducing medications.

Tirzepatide treatment was associated with weight loss comparable to primary study results among participants taking weight-inducing medications.

Practitioners can confidently recommend tirzepatide for weight loss in patients on weight-inducing medications.

Eine Therapie mit GLP-1-RA kann erfolgreich sein, wenn sie mit nicht-medikamentösen Maßnahmen kombiniert wird.

Die Kombination von GLP-1-RA mit Lebensstiländerungen ist entscheidend für den Therapieerfolg.